These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38551691)

  • 1. Systematic review and meta-analysis of randomized controlled trials on the effects of exercise interventions on amyloid beta levels in humans.
    Pucci IM; Aguiar AF; Pucci RM; Casonatto J; Borghi SM
    Exp Brain Res; 2024 May; 242(5):1011-1024. PubMed ID: 38551691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of involuntary chronic physical exercise on beta-amyloid protein in experimental models of Alzheimer's disease: Systematic review and meta-analysis.
    Vasconcelos-Filho FSL; da Rocha Oliveira LC; de Freitas TBC; de Pontes PADS; Rocha-E-Silva RCD; Godinho WDN; Chaves EMC; da Silva CGL; Soares PM; Ceccatto VM
    Exp Gerontol; 2021 Oct; 153():111502. PubMed ID: 34339821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease.
    Brody DL; Jiang H; Wildburger N; Esparza TJ
    Alzheimers Res Ther; 2017 Aug; 9(1):62. PubMed ID: 28818091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
    Chowdhury S; Chowdhury NS
    Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains.
    Gkanatsiou E; Sahlin C; Portelius E; Johannesson M; Söderberg L; Fälting J; Basun H; Möller C; Odergren T; Zetterberg H; Blennow K; Lannfelt L; Brinkmalm G
    Neurosci Lett; 2021 May; 754():135894. PubMed ID: 33848613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal Fluid Amyloid Beta and Tau Concentrations Are Not Modulated by 16 Weeks of Moderate- to High-Intensity Physical Exercise in Patients with Alzheimer Disease.
    Steen Jensen C; Portelius E; Siersma V; Høgh P; Wermuth L; Blennow K; Zetterberg H; Waldemar G; Gregers Hasselbalch S; Hviid Simonsen A
    Dement Geriatr Cogn Disord; 2016; 42(3-4):146-158. PubMed ID: 27643858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysfunction of the blood-brain barrier in Alzheimer's disease: Evidence from human studies.
    Kurz C; Walker L; Rauchmann BS; Perneczky R
    Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12782. PubMed ID: 34823269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Beneficial Role of Exercise on Treating Alzheimer's Disease by Inhibiting β-Amyloid Peptide.
    Tan ZX; Dong F; Wu LY; Feng YS; Zhang F
    Mol Neurobiol; 2021 Nov; 58(11):5890-5906. PubMed ID: 34415486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble amyloid precursor protein-α modulates β-secretase activity and amyloid-β generation.
    Obregon D; Hou H; Deng J; Giunta B; Tian J; Darlington D; Shahaduzzaman M; Zhu Y; Mori T; Mattson MP; Tan J
    Nat Commun; 2012 Apr; 3():777. PubMed ID: 22491325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients.
    Olsson A; Höglund K; Sjögren M; Andreasen N; Minthon L; Lannfelt L; Buerger K; Möller HJ; Hampel H; Davidsson P; Blennow K
    Exp Neurol; 2003 Sep; 183(1):74-80. PubMed ID: 12957490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treadmill exercise enhances synaptic plasticity, but does not alter β-amyloid deposition in hippocampi of aged APP/PS1 transgenic mice.
    Zhao G; Liu HL; Zhang H; Tong XJ
    Neuroscience; 2015 Jul; 298():357-66. PubMed ID: 25917310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical activity and amyloid beta in middle-aged and older adults: A systematic review and meta-analysis.
    Rodriguez-Ayllon M; Solis-Urra P; Arroyo-Ávila C; Álvarez-Ortega M; Molina-García P; Molina-Hidalgo C; Gómez-Río M; Brown B; Erickson KI; Esteban-Cornejo I
    J Sport Health Sci; 2024 Mar; 13(2):133-144. PubMed ID: 37558161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease amyloid-β pathology in the lens of the eye.
    Moncaster JA; Moir RD; Burton MA; Chadwick O; Minaeva O; Alvarez VE; Ericsson M; Clark JI; McKee AC; Tanzi RE; Goldstein LE
    Exp Eye Res; 2022 Aug; 221():108974. PubMed ID: 35202705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis.
    Koyama A; Okereke OI; Yang T; Blacker D; Selkoe DJ; Grodstein F
    Arch Neurol; 2012 Jul; 69(7):824-31. PubMed ID: 22451159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective mechanisms of chronic physical exercise via reduction of β-amyloid protein in experimental models of Alzheimer's disease: A systematic review.
    Vasconcelos-Filho FSL; da Rocha Oliveira LC; de Freitas TBC; de Pontes PADS; da Rocha-E-Silva RC; Chaves EMC; da Silva CGL; Soares PM; Ceccatto VM
    Life Sci; 2021 Jun; 275():119372. PubMed ID: 33745893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different aspects of Alzheimer's disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia.
    Thal DR; Ronisz A; Tousseyn T; Rijal Upadhaya A; Balakrishnan K; Vandenberghe R; Vandenbulcke M; von Arnim CAF; Otto M; Beach TG; Lilja J; Heurling K; Chakrabarty A; Ismail A; Buckley C; Smith APL; Kumar S; Farrar G; Walter J
    Acta Neuropathol Commun; 2019 Nov; 7(1):178. PubMed ID: 31727169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
    Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
    Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.